Gynecologic Oncology

Insight into the typical response to first-line chemotherapy in advanced endometrial cancer and the clinical factors that influence treatment outcomes, with a focus on improving therapies for this high-risk cohort.

Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.

The addition of dostarlimab to carboplatin plus paclitaxel followed by dostarlimab monotherapy significantly improved overall survival compared with placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer.

Explore the case of a 67-year-old patient with recurrent endometrial cancer, highlighting the importance of MMR testing, NGS, and emerging treatment options in today's landscape.

Dive into the evolving landscape of endometrial cancer, including rising incidence, classification, racial disparities, and emerging modalities, as discussed by experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD.

Continued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit vs chemotherapy alone in patients with previously treated advanced endometrial cancer.

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Treatment with platinum-based chemotherapy prior to the administration of chemoradiation led to statistically significant improvements in progression-free survival and overall survival compared with chemoradiation alone in patients with locally advanced cervical cancer.

Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

Atezolizumab plus standard-of-care platinum-based chemotherapy, followed by maintenance therapy with atezolizumab monotherapy, improved progression-free survival vs chemotherapy plus placebo, followed by placebo maintenance therapy, in the frontline treatment of patients with advanced or recurrent endometrial carcinoma particularly in those with mismatch repair–deficient disease.

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

State of Science Summit - Gynecologic Oncology: Chaired by Robert DeBernardo, MD

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.

Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.

Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.

Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.

Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.

Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.

The FDA has granted priority review to a supplemental biologics license application seeking the approval of pembrolizumab in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy, for the treatment of newly diagnosed patients with high-risk, locally advanced cervical cancer.

Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.

Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.

The FDA has granted fast track designation to tulmimetostat for use as a potential therapeutic option in patients with advanced, recurrent, or metastatic endometrial cancer harboring ARID1A mutations and whose disease had progressed on at least 1 prior line of therapy.

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Treatment with tisotumab vedotin-tftv monotherapy led to an improvement in overall survival compared with chemotherapy alone in patients with recurrent or metastatic cervical cancer that progressed on or after frontline therapy.

Administration of the anti–PD-1 antibody prolgolimab in combination with bevacizumab and platinum-doublet chemotherapy resulted in high response rates and a favorable safety profile in patients with recurrent or metastatic cervical cancer.

Alessandro Santin, MD, discusses the investigation of sacituzumab govitecan in patients with recurrent endometrial carcinoma overexpressing TROP2.

The novel anti-PD-1 antibody geptanolimab demonstrated durable antitumor activity and favorable tolerability in patients with recurrent or metastatic PD-L1–positive cervical cancer who previously progressed on a platinum-based regimen.